Literature DB >> 23244189

The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer.

Ashwaq Al Olayan1, Hamad Al Hussaini, Abdul Rahman Jazieh.   

Abstract

Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations. In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23244189     DOI： 10.1016/j.jiph.2012.09.004

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN： 1876-0341            Impact factor:   3.718


  11 in total

Review 1.  Epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Charles N Prabhakar
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Authors:  Mostafa Akbarzadeh Khiavi; Azam Safary; Jaleh Barar; Amir Ajoolabady; Mohammad Hossein Somi; Yadollah Omidi
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

3.  Inhibition of EGFR autophosphorylation plays an important role in the anti-breast cancer efficacy of the dithiocarbamate derivative TM208.

Authors:  Xi-wei Ji; Run-tao Li; Zai-quan Li; Liang Li; Xue-yan Shao; Si-yuan Wang; Yin Yuan; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

4.  A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.

Authors:  Sitanshu S Singh; George Mattheolabakis; Xin Gu; Sita Withers; Achyut Dahal; Seetharama Jois
Journal:  Eur J Med Chem       Date:  2021-02-23       Impact factor: 6.514

5.  Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.

Authors:  Jinn-Li Wang; Chia-Lang Fang; Yu-Tien Tzeng; Han-Lin Hsu; Sey-En Lin; Ming-Chih Yu; Kuan-Jen Bai; Liang-Shun Wang; Hsingjin Eugene Liu
Journal:  J Biomed Sci       Date:  2018-06-28       Impact factor: 8.410

Review 6.  Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer.

Authors:  Lisa Maria Mustachio; Jason Roszik
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-09

Review 7.  Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.

Authors:  Tasia Amelia; Rahmana Emran Kartasasmita; Tomohiko Ohwada; Daryono Hadi Tjahjono
Journal:  Molecules       Date:  2022-01-26       Impact factor: 4.411

8.  Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies.

Authors:  Jun Li; Priyank Kumar; Nagaraju Anreddy; Yun-Kai Zhang; Yi-Jun Wang; Yanglu Chen; Tanaji T Talele; Kanav Gupta; Louis D Trombetta; Zhe-Sheng Chen
Journal:  Oncotarget       Date:  2017-09-16

9.  DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer.

Authors:  Tae Young Kim; Eun Sun Ji; Ju Yeon Lee; Jin Young Kim; Jong Shin Yoo; A Marcell Szasz; Balazs Dome; Gyorgy Marko-Varga; Ho Jeong Kwon
Journal:  Cancers (Basel)       Date:  2020-09-13       Impact factor: 6.639

10.  Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.

Authors:  Jeremy M Drake; Benjamin J Lang; Martin Eduardo Guerrero-Gimenez; Jack Bolton; Christopher A Dow; Stuart K Calderwood; John T Price; Chau H Nguyen
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.